Medroxyprogesterone acetate (MPA) concentrations among HIV-infected depot-medroxyprogesterone acetate (DMPA) users receiving antiretroviral therapy (ART) in Lilongwe, Malawi.

Abstract

OBJECTIVE\nTo compare medroxyprogesterone acetate (MPA) concentrations between HIV-infected women on antiretroviral therapy (ART) and HIV-negative women initiating depot medroxyprogesterone (DMPA) injectable.\n\n\nSTUDY DESIGN\nSecondary analysis of 28 HIV-positive women on non-nucleoside reverse transcriptase inhibitor-containing ART regimens and 10 HIV-negative women randomized to initiate DMPA in a clinical trial of progestin contraception in Malawi.\n\n\nRESULTS\nMPA concentrations were significantly lower among HIV-positive women on ART, compared with HIV-negative women, at week 4 and week 13 (p=.03 for both), but not at day 3 or week 26 post-DMPA initiation.\n\n\nCONCLUSIONS\nAntiretroviral medications may affect MPA metabolism in HIV-positive African women.